Flatiron Health通过与NHSGGC在苏格兰的首次合作扩展全球肿瘤学网络

What You Should Know Flatiron Health UK has partnered with NHS Greater Glasgow and Clyde (NHSGGC), Scotland’s largest health board, establishing Flatiron’s first research footprint in the Scottish healthcare system. The NHSGGC collaboration contributes to a nearly 70% expansion of Flatiron’s international oncology network over the past year, which now spans more than 50 leading sites across the UK, Germany, and Japan. Flatiron’s global oncology dataset is constructed from over six million patient records, with an active operational trajectory targeting 10 million patients globally across US and international health systems. Flatiron’s multidisciplinary teams leverage AI-powered technology alongside clinical and scientific experts to transform structured and unstructured NHS routine care records into research-ready real-world data (RWD). Flatiron’s real-world evidence (RWE) has directly informed more than 40 global regulatory submissions across the FDA, EMA, and other international health authorities, supported by decade-long partnerships with the FDA and NICE. Curating Unstructured EHRs Within Secure Infrastructure The partnership between Flatiron Health UK and NHSGGC focuses on unlocking complex unstructured clinical data—including pathology reports, physician notes, genomic profiling, and imaging results—generated during routine NHS oncology care: Hybrid AI Curation Engine: Flatiron combines expert-validated AI algorithms with human clinical data scientists to structure raw electronic health record (EHR) feeds into research-grade datasets. Trusted Research Environment (TRE): Using its TRE infrastructure (Powered by Lifebit CloudOS), Flatiron enables cross-country cohort analysis and multi-national studies without removing raw patient data from local jurisdictional controls. End-to-End Lifecycle Support: Curated Scottish oncology data directly supports biopharma decision-making across clinical development, regulatory submissions, HTA evaluations, and global commercialization strategies. “Oncology’s most consequential questions require data with the clinical depth, quality, and geographic representation to reflect how cancer care is actually delivered,” stated Michael Bierl, Chief Business Officer at Flatiron Health. “By expanding our network’s geographic reach and patient diversity, we’re giving researchers and biopharma partners a more complete picture of how cancer presents and is treated across different populations.”